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* EVIDENCE-BASED ANSWER 
No direct evidence suggests glucosamine or chrondroitin cause regeneration of cartilage in 
osteoarthritis. Use of glucosamine sulfate in knee osteoarthritis prevents joint space narrowing 
on radiographs (strength of recommendation [SOR]: B, based on 1 randomized controlled trial). 
Intramuscular chondroitin polysulfate prevents radiographic progression of finger osteoarthritis 
(SOR: B, based on 1 randomized controlled trial). 
Both chondroitin sulfate and glucosamine sulfate stimulate chondrocyte growth in vitro and in 
animal models (SOR: D, based on several bench research studies). 
* EVIDENCE SUMMARY 
A systematic review of glucosamine sulfate use for osteoarthritis, based on early research (1956-
1991), found that it has anti-inflammatory properties and rebuilds damaged cartilage. (1) These 
studies evaluated chondrocytes grown in culture and animal models. (1,2) Chondroitin sulfate 
also stimulates chondrocyte biosynthesis in both animal and in vitro studies. There is insufficient 
evidence to demonstrate glucosamine sulfate or chondroitin sulfate stimulates chrondrocyte 
growth in humans with osteoarthritis. (2,3) 
Joint space narrowing on radiographs suggests progression of osteoarthritis. This narrowing is 
thought to imply cartilage destruction or loss due to osteoarthritis. A double-blinded randomized 
controlled trial studied the effect of glucosamine sulfate on tibial-femoral compartment joint 
space narrowing in 212 patients older than 50 with mild to moderate knee osteoarthritis. (4) 
Patients took either 1500 mg/day of glucosamine sulfate or placebo over 3 years. Knee 
radiographs in a standing anterior-posterior view, using visual and digital analysis, were used to 
assess joint space narrowing. (5) The average mean joint space loss was 0.31 mm in the placebo 
group and 0.07 mm in the treatment group (P<.05; 95% confidence interval, 0.13-0.48). 
The clinical relevance of knee joint space narrowing is undetermined. Radiographic evaluation 
of a weight-bearing joint space may not be an accurate or reproducible technique. A study of 15 
patients with mild to moderate knee osteoarthritis used standing and semi-flexed radiographic 
views after an analgesic and nonsteroid anti-inflammatory drug washout period, and 1 to 12 
weeks after resumption of analgesic therapy (mean 6.0 weeks). (6) Knee pain significantly 
decreased radiographic joint space in the standing anterior-posterior position, but not in the 
semiflexed position. Using the standing anterior-posterior method may confound accurate 
interpretation of joint space narrowing and changes in articular cartilage since glucosamine may 
have an anti-inflammatory effect. (6) 
One double-blinded randomized controlled trial, comparing chondroitin sulfate with placebo, 
evaluated joint space in patients with symptomatic hand osteoarthritis. (7) One hundred sixty-
five Caucasian patients, aged 40 to 70 years, were randomized to receive either a 50-mg 
intramuscular injection of chondroitin polysulfate, twice weekly, for 8 weeks, every 4 months, 
versus placebo, or 400 mg of oral chondroitin sulfate, 3 times a day, versus placebo. 
Osteoarthritis progression in the metacarpalphalangeal and interphalangeal joints was assessed 
with radiographs over 3 years. Evaluators used the Anatomic Lesion Progression Scale to assess 
the development of osteophytes and joint space narrowing, with or without subchondral bone 
changes, to determine osteoarthritis progression. This scale makes it very difficult to determine 
whether improvements are clinically significant. 
Chondroitin sulfate and polysulfate did not prevent osteoarthritis from occurring in previously 
normal joints. In joints already affected, intramuscular chondroitin polysulfate significantly 
reduced progression of distal interphalangeal, proximal interpharangeal, and 
metacarpophalangeal joint space narrowing (P<.013), using the progression scale. Oral 
chondroitin sulfate did not prevent progression. (7) 
* RECOMMENDATIONS FROM OTHERS 
The American College of Rheumatology stated in 2000 that recommending glucosomine sulfate 
or chondroitin sulfate for osteoarthritis might be premature due to the methodology, lack of 
standardization, and insufficient information on study designs. More research was recommended. 
(8) 
These products are sold as supplements in the United States. Their purity is often questionable 
and thus may affect study results. When studying glucosamine, the National Institutes of Health 
was forced to manufacture the drug itself due to lack of a reliable amount present in commercial 
products. (9) 
David Priebe, MD, Todd McDiarmid MD, Moses Cone Family Practice, Greensboro, NC; Leslie 
Mackler, MLS, Moses Cone Health System, Greensboro, NC 
* CLINICAL COMMENTARY 
Most family physicians see many patients with osteoarthritis, which can be difficult to treat. My 
patients typically want improvement in their symptoms, traction, and disease progression. 
Although there is good evidence that the use of glucosamine sulphate (but not chondroitin 
sulphate) can improve the common symptoms and functional problems of osteoarthritis, this 
review states it is unclear whether these substances can alter disease progression through 
regeneration of cartilage. 
I tell my patients with osteoarthritis that glucosamine sulfate can help problems like joint pain 
and function, but that we do not have a safe and reliable treatment for reversing the disease or the 
joint damage resulting from it. 
Fred Tudiver, MD, East Tennessee State University, Johnson City 
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